drug:cagrisema CagriSema underperforms in trial We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s
company:novo-nordisk Novo Nordisk is introducing a higher dose of Wegovy Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
company:weight-watchers Novo's expanding collaboration with Weight Watchers Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
drug:wegovy Less for Less: CVS drops Zepbound for Wegovy CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
chemical:semaglutide After two months, Novo Nordisk and HIMS part ways Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
company:novo-nordisk Novo Nordisk patent protections lapse in Canada Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
drug:wegovy Wegovy in pill form is coming Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
politics 2025 Trump Tariffs on Pharmaceutical Imports Trump announces soon-to-be tariffs on pharmaceutical imports, we dig into how much Novo Nordisk and Eli Lilly could be affected.
category:news Hims pivots to branded Tirzepatide, generic Liraglutide Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
research STRIDE study: GLP1s vs peripheral artery disease (PAD) Walk farther with GLP1s -- results from the STRIDE study show Semaglutide effective for treating Peripheral Artery Disease (PAD)
category:news Novo Nordisk licenses GLP1 drug from United BioTechnology, a Chinese research firm Novo Nordisk licenses the right to sell a new GLP1 being developed in China -- 15% weight loss in 12 weeks (in an admittedly small study).
company:novo-nordisk Novo Nordisk offers cheaper Wegovy Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
category:watercooler Shortages threaten corporate profits, likely to end soon We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news Ozempic approved for Chronic Kidney Disease The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
company:novo-nordisk Novo's Amycretin delivers great Phase 2 results Novo Nordisk's Amycretin produces stellar results in Phase 2 trials -- we dive into Amycretin and other new drugs to see how it compares.
government Government Price negotiations on Ozempic and Wegovy The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:howto What's the best injection site for GLP1s? What's the best site for injecting Ozempic, Wegovy, Mounjaro, or Zepbound? We check anecdata, manufacturers, and 3rd parties.
drug:amycretin Novo's new GLP1: Amycretin Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
chemical:semaglutide 24% Less kidney disease risk with Semaglutide (Ozempic) Can we trust research funded by Novo Nordisk which found a 24% decrease in kidney disease risk for people on Semaglutide (Ozempic)?
